“Our founding objective was to simplify what was a complex, expensive and environmentally challenging supply chain for specific alkaloid APIs, primarily the APIs used in treatments for opioid use disorder and other substance use disorders – Buprenorphine, Naloxone and Naltrexone”

Our pioneering production methods blend synthetic biology and traditional chemistry. Flexible intermediates in this proprietary synthetic pathway streamline the manufacture of a wide range of alkaloid molecules. This enables River Stone Biotech to produce specialty molecules without traditionally associated toxic chemistry, yielding an improved environmental footprint at reduced cost.

Our highly experienced management team has taken multiple projects from concept through method development and into commercial-scale production.

River Stone Biotech recognizes the need for increasing volumes of the APIs used in life-changing treatments for opioid overdose, opioid use disorder, alcohol use disorder and pain. These APIs represent the priority portfolio offering of River Stone Biotech.

We work with a small number of global providers to establish a virtual, cross-functional operation that enables our API offering. Working together we can reduce the cost and environmental impact of these APIs, which are so important in treating overdose and substance use disorders. River Stone Biotech is always open to collaboration with industry and academic partners, particularly those collaborators interested in creating successful new generics partnerships.

River Stone Biotech is headquartered in Wilmington, Delaware, US. An early stage research function in Australia supports our primary research & development site in Copenhagen, Denmark. Here, expert scientists perform high-quality research to innovate and to optimize production methods. In addition we have a branch office of the US in the UK that manages our strategic partnerships and technical operations.

Working together we can create successful partnerships to
enable and expand our API offering.